What is regulatory affairs in pharma — a B.Pharma-first explainer

When Ranbaxy submitted its bioequivalence data to the US FDA, somebody inside the company had to compile that submission, format it to specification, and put it in front of regulators as complete and truthful. That "somebody" is the regulatory affairs function. When the data turned out to be fabricated, RA is the department that sat directly between the fraud and the agency that was supposed to catch it — whether or not any individual RA associate knew what was happening.

That's not a comfortable opening for an article about a career path. But it's the fastest way to understand what regulatory affairs actually is, because most explanations of the job start from the wrong end — a bridge between the company and the government, negotiating approvals, and so on. All true, but abstract. The Ranbaxy case makes it concrete: RA is the function responsible for what regulators actually see. Everything else in this article follows from that one fact.

What is regulatory affairs in the pharmaceutical industry?

Regulatory affairs is the function inside a pharma company responsible for making sure a drug — from its earliest animal studies through its years on the market — meets every legal and scientific requirement a government regulator sets, and for compiling the documentation that proves it. An RA professional does not discover drugs and does not manufacture them. They translate what the scientists and manufacturers did into the exact format a regulator like India's CDSCO, the US FDA, or the EMA requires, and they manage the back-and-forth — the queries, the corrections, the negotiations — until the regulator grants approval.

If you've read our piece on the Ranbaxy case, you already understand the stakes: RA is not a paperwork afterthought bolted onto real science. It's the checkpoint between what a company did in the lab and what a regulator is told was done.

What an RA associate actually does, day to day

The job changes shape depending on where a drug is in its life, and this is the part most explainers skip.

Before human trials even start, RA is already involved. When a company wants to test a new drug in animals, RA advises on how those preclinical studies need to be designed so the resulting data will actually be acceptable to a regulator later — following Good Laboratory Practice standards. Get this wrong, and years of toxicology work can be rejected on a technicality.

Before a drug reaches human subjects, RA prepares the application that lets a clinical trial happen at all — in India, this runs through the New Drugs and Clinical Trials Rules, 2019 and CDSCO's Schedule Y, which lay out exactly what a Clinical Trial Application needs to contain. RA also acts as the point of contact between the company and both the regulator and the ethics committees overseeing patient safety during the trial, making sure trial protocols follow Good Clinical Practice.

When trials succeed, RA compiles what is genuinely one of the largest documents a pharma company produces: the marketing authorisation dossier. This is where the Common Technical Document format comes in — a five-module structure (administrative information, summaries, quality/CMC data, non-clinical study reports, and clinical study reports) that the International Council for Harmonisation designed specifically so a single dossier structure could work across multiple countries' regulators. In its electronic form, this is called an eCTD. Building one correctly, cross-referencing hundreds of thousands of pages, and responding to a regulator's follow-up queries without contradicting an earlier submission — that's the actual day-to-day skill the job tests for, far more than any single piece of scientific knowledge.

After approval, the job doesn't stop. Every time a company changes a manufacturing process, switches a raw material supplier, or updates a testing method, RA has to file a variation proving the product is still the same drug it was approved as. RA also reviews every piece of promotional material and every product label before it goes out, to make sure nothing claims an unapproved use. And RA works closely with the pharmacovigilance team — when a safety signal shows up in adverse event data, RA is the one who manages the regulatory side of updating a warning label or, in the worst case, pulling a product from the market.

Regulatory affairs vs QA vs pharmacovigilance vs medical writing

This is the single most common confusion for freshers, and it's worth resolving cleanly rather than leaving it vague.

The confusion usually comes from the fact that these four functions constantly hand work to each other on the same drug. A medical writer drafts a clinical study report; RA slots it into Module 5 of the dossier; QA has already made sure the manufacturing data feeding into Module 3 is accurate; and once the drug is approved, PV starts monitoring it and feeds anything concerning back to RA. They're distinct jobs with distinct skill sets, but none of them work in isolation from the others.

Do you need an M.Pharm, or can a B.Pharm get in?

Some university-run explainers on this topic imply that an M.Pharm specialisation in regulatory affairs is close to mandatory. That's an overstatement worth correcting directly, especially since the source making that claim is usually trying to sell you the M.Pharm program.

A B.Pharm is a genuinely viable entry point into RA, especially for associate and trainee-level roles at companies that value someone who can be trained on the actual submission process rather than someone who already has a regulatory affairs degree. What actually matters at the fresher stage is being able to demonstrate, even in a CV or interview, that you understand what a dossier is, what CTD structure looks like, and that you can read and follow a regulatory guideline document without getting lost. An M.Pharm in regulatory affairs helps you skip some of that learning curve and can matter more for mid-career moves into strategy-heavy roles — but it is not the only door in.

The Indian regulatory structure an RA associate actually works inside

India's system is more fragmented than a single "CDSCO approves drugs" sentence suggests, and understanding the split matters for the job.

The Central Drugs Standard Control Organisation, headed by the Drugs Controller General of India and sitting under the Directorate General of Health Services, is the national body responsible for approving new drugs, clinical trials, and import licenses. Domestic submissions to CDSCO largely route through its online SUGAM portal.

But manufacturing, sales, and distribution licenses are handled separately, at the state level, by each state's own Food and Drug Administration. An RA professional working on an Indian launch has to satisfy CDSCO's national requirements and the relevant state FDA's manufacturing and licensing requirements at the same time — two different systems, two different sets of paperwork, often two different timelines. This is the same central-versus-state fragmentation that shows up in our Coldrif cough syrup piece, where gaps between central and state drug enforcement were part of what let a fatal manufacturing failure go undetected for as long as it did. RA sitting inside that same fragmented structure, on the compliance side rather than the enforcement side, is exactly why the job carries the weight it does.

What the job actually pays

Treat any specific number here as a general industry indication rather than a guaranteed figure — pay varies by company, city, and how in-demand your specific skill set is. Industry salary trackers and recruiter data broadly put a fresher RA associate in India in the range of roughly ₹3 to 4.5 lakh a year. With three to five years of experience and a move into a managerial or specialist-strategy role, that band moves up meaningfully — often into double digits. At the senior end — director or VP-level roles managing global regulatory strategy across dozens of markets — compensation can run considerably higher again. The honest takeaway: RA is not a fast-money role at entry level, but it compounds well with experience, because regulatory expertise is genuinely hard to replace once you've built it.

What went wrong at Ranbaxy, from an RA standpoint

It's worth returning to where this article started, now that the job itself is clear. Ranbaxy's fraud wasn't a failure of chemistry — the underlying manufacturing capability was real. It was a failure of what got submitted to regulators being false: fabricated bioequivalence and stability data, dressed up to look like a legitimate dossier. The FDA's response was to place Ranbaxy's Paonta Sahib facility under an Application Integrity Policy designation — which does something specific and severe: it flips the burden of proof, so the company has to prove its data is genuine rather than the regulator assuming basic honesty. That is the single clearest illustration available of what regulatory affairs, done properly, exists to prevent — not a rejected application, but the moment a regulator can no longer trust anything a company submits.

If you want the full account of how that unfolded, the case study is on this site, and it's the article this whole piece is built around understanding.

Quick answers

What is regulatory affairs in the pharmaceutical industry?

It's the function responsible for ensuring a drug meets every legal and scientific requirement a regulator sets, and for compiling and submitting the documentation — from early animal studies through to post-market variations — that proves it.

What does a regulatory affairs associate actually do day to day in Indian pharma?

Depending on the drug's stage, an RA associate prepares clinical trial applications, compiles CTD/eCTD dossiers for marketing approval, manages regulator queries, reviews promotional material and labels for compliance, and files post-approval variations when manufacturing or supply details change.

What is the difference between regulatory affairs, QA, and pharmacovigilance?

RA compiles and submits regulatory dossiers and manages the regulator relationship. QA ensures the manufacturing process itself follows GMP and internal SOPs. Pharmacovigilance monitors and reports adverse drug events after a product reaches the market. They constantly hand off work to each other on the same product but are distinct functions.

Can a B.Pharm graduate get into regulatory affairs without an M.Pharm?

Yes, particularly at the associate/trainee level. An M.Pharm in regulatory affairs can help for mid-career strategy roles, but it is not a mandatory entry requirement, despite what some university program pages suggest.

What is CTD/eCTD and why does every RA job posting mention it?

The Common Technical Document is a five-module dossier structure — covering administrative info, summaries, quality/manufacturing data, non-clinical data, and clinical data — designed by the ICH so the same submission structure can be used across multiple countries' regulators. The eCTD is its electronic format. Nearly every RA job mentions it because building and maintaining one correctly is the core technical skill of the role.

What is the realistic starting salary for an RA associate/trainee in India?

Roughly ₹3 to 4.5 lakh a year at the fresher level, based on general industry salary data — rising meaningfully with experience, particularly after 3-5 years when a move into managerial or specialist roles becomes realistic.

What went wrong at Ranbaxy from a regulatory affairs standpoint?

Ranbaxy submitted fabricated bioequivalence and stability data to the FDA as though it were genuine — the exact failure regulatory affairs exists to prevent. The FDA's response, placing the company's plant under an Application Integrity Policy designation, forced Ranbaxy to prove its data was authentic rather than have that assumed, which is the clearest real-world illustration of what the RA function guards against.

If this was useful, the next piece worth reading is on Ranbaxy and the FDA — the full case behind the failure this article uses to explain what regulatory affairs actually guards against.